Last updated August 24, 2026
Key finding
Awiqli™ produced a statistically significant improvement in glycemic control compared with insulin glargine U-100 or insulin degludec U-100.
The study evaluated Awiqli™ (insulin icodec-abae) for type 2 diabetes, finding significant improvements in glycemic control compared to standard insulins.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated Awiqli™ (insulin icodec-abae) for type 2 diabetes, finding significant improvements in glycemic control compared to standard insulins.
Improving glycemic control is crucial for managing type 2 diabetes and reducing the risk of complications. Awiqli™ offers a promising alternative to existing insulin therapies, potentially enhancing patient outcomes and quality of life. Understanding its side effects is essential for safe clinical use.
Effectiveness data was unclear for some outcomes. The study's population may not represent all type 2 diabetes patients. Adverse reactions were reported but not quantified.
Published in
Publication details and source links for this paper.
Muhammad AA, Muhammad HA, Muhammad DA. Awiqli™ (insulin icodec-abae) represents a meaningful advancement in basal insulin therapy for type 2 diabetes. Annals of Medicine and Surgery. 2026;88(6):3787-3790. doi:10.1097/MS9.0000000000005132
Awiqli™ significantly improved glycemic control compared to insulin glargine U-100.
Awiqli™ significantly improved glycemic control compared to insulin degludec U-100.
Common adverse reactions included hypoglycemia, injection site reactions, and weight gain.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin icodec (Awiqli) and Improvement in glycemic control for newly diagnosed patients, Injection-site adverse reactions.
This study contributes evidence to
Primary intervention
Insulin icodec (Awiqli)
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
2
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Insulin icodec (Awiqli) → Improvement in glycemic control for newly diagnosed patients
Insulin icodec (Awiqli) → Improvement in glycemic control for newly diagnosed patients
Insulin icodec (Awiqli) → Injection-site adverse reactions
Insulin icodec (Awiqli) → Injection-site adverse reactions
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin icodec (Awiqli) appears to improve improvement in glycemic control for newly diagnosed patients.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Improvement in glycemic control for newly diagnosed patients
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear effect of Insulin icodec (Awiqli) on injection-site adverse reactions.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Injection-site adverse reactions
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
